Autor: "Harrigan, P Richard" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.
Autorzy:: Orkin C; Queen Mary University London, London, UK.
Cahn P; Fundacion Huesped, Buenos Aires, Argentina.; Buenos Aires University Medical School, Buenos Aires, Argentina.
Castagna A; Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy.
Emu B; Yale School of Medicine, New Haven, Connecticut, USA.
Harrigan PR; University of British Columbia, Vancouver, BC, Canada.
Kuritzkes DR; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nelson M; Chelsea and Westminster Hospital, London, UK.
Schapiro J; Sheba Medical Center, Tel Aviv, Israel.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2022 Oct; Vol. 23 (9), pp. 936-946. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV-1*
Drug Resistance, Viral ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.
Autorzy:: Parkin NT; Data First Consulting, Inc., Sebastopol, CA 95472, USA.
Avila-Rios S; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City 14080, Mexico.
Bibby DF; National Infection Service, Public Health England, London NW9 5EQ, UK.
Brumme CJ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada.; Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Eshleman SH; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Harrigan PR; Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Howison M; Research Improving People's Lives, Providence, RI 02909, USA.
Hunt G; National Institute for Communicable Diseases, Johannesburg 2192, South Africa.
Ji H; National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada.
Kantor R; Division of Infectious Diseases, Brown University Alpert Medical School, Providence, RI 02912, USA.
Ledwaba J; National Institute for Communicable Diseases, Johannesburg 2192, South Africa.
Lee ER; National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada.
Matías-Florentino M; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City 14080, Mexico.
Mbisa JL; National Infection Service, Public Health England, London NW9 5EQ, UK.
Noguera-Julian M; IrsiCaixa AIDS Research Institute, Badalona, 08916 Catalonia, Spain.
Paredes R; IrsiCaixa AIDS Research Institute, Badalona, 08916 Catalonia, Spain.
Rivera-Amill V; Center for Research Resources-Immunology Reference Laboratory, Ponce Health Sciences University-Ponce Research Institute, Ponce, PR 00716, USA.
Swanstrom R; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA.
Zaccaro DJ; RTI International, Research Triangle Park, NC 27709, USA.
Zhang Y; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Zhou S; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA.
Jennings C; Rush Medical College, Chicago, IL 60612, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2020 Jun 27; Vol. 12 (7). Date of Electronic Publication: 2020 Jun 27.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: High-Throughput Nucleotide Sequencing*
Drug Resistance, Viral/*genetics
Genotyping Techniques/*methods
HIV-1/*genetics
Laboratories/*standards
Genetic Variation ; Genotype ; HIV Reverse Transcriptase/genetics ; HIV-1/drug effects ; HIV-1/enzymology ; Mutation ; Peptide Hydrolases/genetics ; Sequence Analysis, DNA

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework.
Autorzy:: Capina R; National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada.
Li K; National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada.
Kearney L; Scientific Informatics Services at National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Vandamme AM; Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.; Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universida de Nova de Lisboa, 1349-008 Lisbon, Portugal.
Harrigan PR; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Van Laethem K; Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.; AIDS Reference Laboratory, University Hospital Leuven, 3000 Leuven, Belgium.; Pokaż więcej
Źródło:: Viruses [Viruses] 2020 Jun 14; Vol. 12 (6). Date of Electronic Publication: 2020 Jun 14.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: Drug Resistance, Viral*
HIV Infections/*virology
HIV-1/*genetics
High-Throughput Nucleotide Sequencing/*standards
Animals ; Clinical Laboratory Information Systems ; HIV-1/classification ; HIV-1/drug effects ; HIV-1/isolation & purification ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Quality Control

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Autorzy:: Paredes R; IrsiCaixa AIDS Research Institute, Badalona, Spain.
Tzou PL; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
van Zyl G; Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa.
Barrow G; Centre for HIV/AIDS Research, Education and Services (CHARES), Department of Medicine, University of the West Indies, Kingston Jamaica.
Camacho R; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
Carmona S; Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.
Grant PM; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
Gupta RK; UCL, Department of Infection, London, WC1E 6BT, United Kingdom.
Hamers RL; Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.
Harrigan PR; BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Jordan MR; Tufts University School of Medicine, Boston, MA, United States of America.
Kantor R; Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, United States of America.
Katzenstein DA; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
Kuritzkes DR; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America.
Maldarelli F; HIV Dynamics and Replication Program, CCR, National Cancer Institute, NIH, Translational Research Unit, Frederick, MD, United States of America.
Otelea D; Molecular Diagnostics Laboratory, National Institute for Infectious Diseases, Bucharest, Romania.
Wallis CL; BARC-SA and Lancet Laboratories, Johannesburg, South Africa.
Schapiro JM; National Hemophilia Center, Tel Hashomer, Israel.
Shafer RW; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Jul 28; Vol. 12 (7), pp. e0181357. Date of Electronic Publication: 2017 Jul 28 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents/*pharmacology
HIV-1/*drug effects
HIV-1/*genetics
Reverse Transcriptase Inhibitors/*pharmacology
Alkynes ; Benzoxazines/pharmacology ; Cyclopropanes ; Dideoxynucleosides/pharmacology ; Drug Resistance, Viral/genetics ; Genotype ; Heterocyclic Compounds, 3-Ring/pharmacology ; Lamivudine/pharmacology ; Lopinavir/pharmacology ; Nelfinavir/pharmacology ; Oxazines ; Piperazines ; Pyridones ; Ritonavir/pharmacology ; Zidovudine/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification.
Autorzy:: Lima VD; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.; Division of AIDS, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Wang L; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Brumme C; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Wu L; Statistics Department, University of British Columbia, Vancouver, British Columbia, Canada.
Montaner JS; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.; Division of AIDS, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Harrigan PR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.; Division of AIDS, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Feb 02; Vol. 12 (2), pp. e0171155. Date of Electronic Publication: 2017 Feb 02 (Print Publication: 2017).
Typ publikacji:: Journal Article; Validation Study
MeSH Terms:: HIV Infections/*virology
HIV-1/*genetics
HIV-1/*isolation & purification
RNA, Viral/*blood
RNA, Viral/*genetics
Viral Load/*methods
Adult ; Anti-HIV Agents/therapeutic use ; CD4 Lymphocyte Count ; Female ; HIV Infections/blood ; HIV Infections/drug therapy ; Humans ; Limit of Detection ; Male ; Middle Aged ; Viral Load/statistics & numerical data

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.
Autorzy:: Balachandran A; Department of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Wong R; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Stoilov P; Department of Biochemistry, University of West Virginia, Morgantown, WV, USA.
Pan S; Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Blencowe B; Department of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.; Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Cheung P; British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard St., Vancouver, BC, Canada.
Harrigan PR; British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard St., Vancouver, BC, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Cochrane A; Department of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada. .; Pokaż więcej
Źródło:: Retrovirology [Retrovirology] 2017 Jan 26; Vol. 14 (1), pp. 7. Date of Electronic Publication: 2017 Jan 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents/*isolation & purification
Anti-HIV Agents/*pharmacology
Gene Expression Regulation, Viral/*drug effects
HIV-1/*genetics
RNA Processing, Post-Transcriptional/*drug effects
rev Gene Products, Human Immunodeficiency Virus/*antagonists & inhibitors
tat Gene Products, Human Immunodeficiency Virus/*antagonists & inhibitors
Anti-HIV Agents/chemistry ; Cells, Cultured ; HIV-1/physiology ; Humans ; Models, Molecular ; Molecular Structure ; RNA, Viral/analysis ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Virus Replication/drug effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
Autorzy:: Rhee SY; Department of Medicine, Stanford University, Stanford, California, United States of America. Leuven—University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.
Blanco JL; Hospital Clinic Universitari-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Jordan MR; Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Taylor J; Department of Statistics, Stanford University, Stanford, California, United States of America.
Lemey P; KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.
Varghese V; Department of Medicine, Stanford University, Stanford, California, United States of America.
Hamers RL; Department of Global Health and Internal Medicine, Academic Medical Center of the University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Bertagnolio S; World Health Organization, Geneva, Switzerland.
Rinke de Wit TF; Department of Global Health and Internal Medicine, Academic Medical Center of the University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Aghokeng AF; Virology Laboratory CREMER-IMPM, Yaoundé, Cameroon.
Albert J; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Avi R; Department of Microbiology, University of Tartu, Tartu, Estonia.
Avila-Rios S; National Institute of Respiratory Diseases, Centre for Research in Infectious Diseases, Mexico City, Mexico.
Bessong PO; HIV/AIDS & Global Health Research Programme, Department of Microbiology, University of Venda, Thohoyandou, South Africa.
Brooks JI; National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Boucher CA; Department of Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, Netherlands.
Brumme ZL; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Busch MP; Blood Systems Research Institute, San Francisco, California, United States of America.
Bussmann H; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Chaix ML; Laboratoire de Virologie, Hôpital Saint Louis, Université Paris Diderot, INSERM U941, Paris, France.
Chin BS; Center for Infectious Diseases, National Medical Center, Seoul, Republic of Korea.
D'Aquin TT; CIRBA-Programme PACCI, Abidjan, Côte d'Ivoire.
De Gascun CF; UCD National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Derache A; Department of Virology, Pitie-Salpetriere Hospital, Paris, France.
Descamps D; Laboratoire de Virologie, Assistance Publique-Hôpitaux de Paris Hôpital Bichat-Claude Bernard, INSERM UMR 1137, Université Paris Diderot, Paris, France.
Deshpande AK; Department of Medicine, Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals, Mumbai, India.
Djoko CF; Global Viral Cameroon, Intendance Round About, EMAT/CRESAR, Yaoundé, Cameroon.
Eshleman SH; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Fleury H; Laboratoire de Virologie, Centre Hospitalier Universitaire de Bordeaux, CNRS UMR 5234, Université de Bordeaux, Bordeaux, France.
Frange P; Microbiology Department, Hôpital Necker-Enfants Malades, Paris, France.
Fujisaki S; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Harrigan PR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Hattori J; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Holguin A; Department of Microbiology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Hunt GM; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
Ichimura H; Department of Viral Infection and International Health, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kaleebu P; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Katzenstein D; Department of Medicine, Stanford University, Stanford, California, United States of America.
Kiertiburanakul S; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Kim JH; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Kim SS; Division of AIDS, Korea National Institute of Health, Osong, Chungcheongbuk-do, Republic of Korea.
Li Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Lutsar I; Department of Microbiology, University of Tartu, Tartu, Estonia.
Morris L; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
Ndembi N; Institute of Human Virology, Abuja, Nigeria.
Ng KP; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Paranjape RS; National AIDS Research Institute, Indian Council of Medical Research, Pune, India.
Peeters M; Unité Mixte Internationale 233, Institut de Recherche pour le Développement, INSERM U1175, and University of Montpellier, 34394 Montpellier, France; Computational Biology Institute, Montpellier, France.
Poljak M; Institute of Microbiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Price MA; Department of Medical Affairs, International AIDS Vaccine Initiative, New York, New York, United States of America; Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, California, United States of America.
Ragonnet-Cronin ML; University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Reyes-Terán G; National Institute of Respiratory Diseases, Centre for Research in Infectious Diseases, Mexico City, Mexico.
Rolland M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Sirivichayakul S; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Smith DM; University of California San Diego, La Jolla, California, United States of America.
Soares MA; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Soriano VV; Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Ssemwanga D; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Stanojevic M; Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Stefani MA; Federal University of Goias, Goias, Brazil.
Sugiura W; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Sungkanuparph S; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Tanuri A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Tee KK; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Truong HM; Department of Medicine, University of California, San Francisco, California, United States of America.
van de Vijver DA; Department of Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, Netherlands.
Vidal N; Institut de Recherche pour le Développement, University of Montpellier 1, Montpellier, France.
Yang C; International Laboratory Branch, Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Yang R; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Yebra G; Department of Microbiology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Ioannidis JP; Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, California, United States of America; Meta-Research Innovation Center at Stanford, Stanford University, Stanford, California, United States of America.
Vandamme AM; KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium; Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.
Shafer RW; Department of Medicine, Stanford University, Stanford, California, United States of America.; Pokaż więcej
Źródło:: PLoS medicine [PLoS Med] 2015 Apr 07; Vol. 12 (4), pp. e1001810. Date of Electronic Publication: 2015 Apr 07 (Print Publication: 2015).
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Base Sequence*
Drug Resistance, Viral*
Mutation*
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV Reverse Transcriptase/*genetics
HIV-1/*genetics
Africa ; Americas ; Anti-HIV Agents/pharmacology ; Asia ; Europe ; HIV Infections/virology ; HIV Reverse Transcriptase/antagonists & inhibitors ; HIV-1/drug effects ; Humans ; Molecular Epidemiology ; Phylogeny

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: "Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1.
Autorzy:: Knapp DJ; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
McGovern RA; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Poon AF; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Zhong X; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Chan D; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Swenson LC; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Dong W; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Harrigan PR; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Jun 24; Vol. 9 (6), pp. e99508. Date of Electronic Publication: 2014 Jun 24 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections/*virology
HIV-1/*genetics
High-Throughput Nucleotide Sequencing/*methods
Sequence Analysis, RNA/*methods
Humans ; Reproducibility of Results

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy.
Autorzy:: Lee GQ; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
Dong W; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Mo T; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Knapp DJ; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
Brumme CJ; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
Woods CK; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Kanters S; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Yip B; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Harrigan PR; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Jun 06; Vol. 9 (6), pp. e99000. Date of Electronic Publication: 2014 Jun 06 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Evolution, Molecular*
HIV-1/*drug effects
HIV-1/*physiology
Viral Tropism/*drug effects
Viremia/*diagnosis
Viremia/*virology
Adult ; Antiretroviral Therapy, Highly Active ; Base Sequence ; Female ; HIV-1/genetics ; Humans ; Male ; Middle Aged ; Selection, Genetic/drug effects ; Viremia/drug therapy

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.
Autorzy:: Cotton LA; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Kuang XT; Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Le AQ; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Carlson JM; Microsoft Research, Los Angeles, California, United States of America.
Chan B; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Chopera DR; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
Brumme CJ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Markle TJ; Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Martin E; Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Shahid A; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Anmole G; Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Mwimanzi P; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Nassab P; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Penney KA; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Rahman MA; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Milloy MJ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Schechter MT; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Markowitz M; Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, United States of America.
Carrington M; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Ragon Institute of MGH, MIT and Harvard University, Cambridge, Massachusetts, United States of America.
Walker BD; Ragon Institute of MGH, MIT and Harvard University, Cambridge, Massachusetts, United States of America.
Wagner T; San Francisco Department of Public Health, San Francisco, California, United States of America.
Buchbinder S; San Francisco Department of Public Health, San Francisco, California, United States of America.
Fuchs J; San Francisco Department of Public Health, San Francisco, California, United States of America.
Koblin B; New York Blood Center, New York, New York, United States of America.
Mayer KH; Fenway Community Health, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America.
Harrigan PR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Brockman MA; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Poon AF; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Brumme ZL; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.; Pokaż więcej
Źródło:: PLoS genetics [PLoS Genet] 2014 Apr 24; Vol. 10 (4), pp. e1004295. Date of Electronic Publication: 2014 Apr 24 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Adaptation, Physiological/*genetics
HIV Infections/*genetics
HIV-1/*genetics
Amino Acid Sequence ; Genotype ; HLA Antigens/genetics ; Humans ; Male ; Molecular Sequence Data ; North America ; Phylogeny ; Polymorphism, Genetic/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB.
Autorzy:: Dahabieh MS
Ooms M; Department of Microbiology, The Global Health and Emerging Pathogens Institute; Mount Sinai School of Medicine, 1468 Madison Avenue, Annenberg building 18-50, New York, NY 10029, USA. .
Brumme C
Taylor J
Harrigan PR
Simon V
Sadowski I; Pokaż więcej
Źródło:: Retrovirology [Retrovirology] 2014 Feb 07; Vol. 11, pp. 17. Date of Electronic Publication: 2014 Feb 07.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Virus Latency*
Virus Replication*
HIV-1/*immunology
HIV-1/*physiology
NF-kappa B/*metabolism
T-Lymphocytes/*immunology
T-Lymphocytes/*virology
Humans ; Jurkat Cells ; Virus Integration

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes.
Autorzy:: Mann JK; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada. mark_.
Byakwaga H
Kuang XT
Le AQ
Brumme CJ
Mwimanzi P
Omarjee S
Martin E
Lee GQ
Baraki B
Danroth R
McCloskey R
Muzoora C
Bangsberg DR
Hunt PW
Goulder PJ
Walker BD
Harrigan PR
Martin JN
Ndung'u T
Brockman MA
Brumme ZL; Pokaż więcej
Źródło:: Retrovirology [Retrovirology] 2013 Sep 16; Vol. 10, pp. 100. Date of Electronic Publication: 2013 Sep 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Host-Pathogen Interactions*
CD4 Antigens/*biosynthesis
HIV-1/*physiology
Histocompatibility Antigens Class I/*biosynthesis
nef Gene Products, Human Immunodeficiency Virus/*metabolism
Adult ; Africa ; CD4-Positive T-Lymphocytes/virology ; Cell Line ; Down-Regulation ; Female ; Genotype ; HIV Infections/virology ; HIV-1/classification ; HIV-1/genetics ; HIV-1/isolation & purification ; Humans ; Male ; North America

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data.
Autorzy:: Poon AF; BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. />Swenson LC
Bunnik EM
Edo-Matas D
Schuitemaker H
van 't Wout AB
Harrigan PR; Pokaż więcej
Źródło:: PLoS computational biology [PLoS Comput Biol] 2012; Vol. 8 (11), pp. e1002753. Date of Electronic Publication: 2012 Nov 01.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Evolution, Molecular*
High-Throughput Nucleotide Sequencing*
Computational Biology/*methods
HIV Infections/*virology
HIV-1/*genetics
Host-Pathogen Interactions/*genetics
Algorithms ; Amino Acid Sequence ; Genetic Fitness/genetics ; Genotype ; HIV-1/pathogenicity ; Humans ; Molecular Sequence Data ; Mutation ; Phenotype ; Phylogeny ; RNA, Viral/chemistry ; RNA, Viral/genetics ; Receptors, CCR5 ; Receptors, CXCR4

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing.
Autorzy:: Lee GQ; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Swenson LC
Poon AF
Martin JN
Hatano H
Deeks SG
Harrigan PR; Pokaż więcej
Źródło:: PloS one [PLoS One] 2012; Vol. 7 (9), pp. e46181. Date of Electronic Publication: 2012 Sep 26.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV-1/*drug effects
High-Throughput Nucleotide Sequencing/*methods
Leukocytes, Mononuclear/*virology
Plasma/*virology
Pyrrolidinones/*pharmacology
Humans ; Male ; Middle Aged ; Prospective Studies ; Raltegravir Potassium

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.
Autorzy:: Bunnik EM; Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Swenson LC
Edo-Matas D
Huang W
Dong W
Frantzell A
Petropoulos CJ
Coakley E
Schuitemaker H
Harrigan PR
van 't Wout AB; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2011 Jun; Vol. 7 (6), pp. e1002106. Date of Electronic Publication: 2011 Jun 23.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Genetic Variation*
Receptors, CCR5*
Receptors, CXCR4*
Sequence Analysis, RNA*
HIV-1/*genetics
Biological Evolution ; HIV Infections ; Humans ; RNA, Viral/genetics ; Time Factors ; env Gene Products, Human Immunodeficiency Virus/genetics